3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association Between SNPs in the One-Carbon Metabolism Pathway and the Risk of Female Breast Cancer in a Chinese Population

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          The aim of this study is to assess the relationship between the single-nucleotide polymorphism (SNP) in the one-carbon metabolism pathway ( MTR rs1805087; MTHFR rs1801133; ALDH1L1 rs2002287, rs2276731; DNMT1 rs16999593, rs2228611; DNMT3B rs2424908) and the risk of female breast cancer (BC) in a Chinese population.

          Methods

          A population-based case–control study was conducted, involving a total of 439 BC patients and 439 age-matched healthy controls. We adopted Sequence MASSarray to identify genotyping, and used immunohistochemistry (IHC) to test the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) in tumor tissue.

          Results

          We found that rs16999593 (TC/CC vs TT: adjusted OR=1.38, 95% CI: 1.03–1.84, p=0.030) was associated with an increased risk of BC, while rs2228611 was related to a decreased BC risk (GA/AA vs GG: adjusted OR=0.74, 95% CI: 0.56–0.97, p=0.030). In addition, stratified analysis revealed that DNMT1 rs16999593, rs2228611 and ALDH1L1 rs2002287 contributed to the risk of BC, with associations with ER, PR and HER-2 expression.

          Conclusion

          In summary, this study revealed that DNMT1 rs16999593 and rs2228611 were associated with BC risk.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            One-Carbon Metabolism in Health and Disease.

            One-carbon (1C) metabolism, mediated by the folate cofactor, supports multiple physiological processes. These include biosynthesis (purines and thymidine), amino acid homeostasis (glycine, serine, and methionine), epigenetic maintenance, and redox defense. Both within eukaryotic cells and across organs, 1C metabolic reactions are compartmentalized. Here we review the fundamentals of mammalian 1C metabolism, including the pathways active in different compartments, cell types, and biological states. Emphasis is given to recent discoveries enabled by modern genetics, analytical chemistry, and isotope tracing. An emerging theme is the biological importance of mitochondrial 1C reactions, both for producing 1C units that are exported to the cytosol and for making additional products, including glycine and NADPH. Increased clarity regarding differential folate pathway usage in cancer, stem cells, development, and adult physiology is reviewed and highlights new opportunities for selective therapeutic intervention.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Risk Factors and Preventions of Breast Cancer

              Breast cancer is the second leading cause of cancer deaths among women. The development of breast cancer is a multi-step process involving multiple cell types, and its prevention remains challenging in the world. Early diagnosis of breast cancer is one of the best approaches to prevent this disease. In some developed countries, the 5-year relative survival rate of breast cancer patients is above 80% due to early prevention. In the recent decade, great progress has been made in the understanding of breast cancer as well as in the development of preventative methods. The pathogenesis and tumor drug-resistant mechanisms are revealed by discovering breast cancer stem cells, and many genes are found related to breast cancer. Currently, people have more drug options for the chemoprevention of breast cancer, while biological prevention has been recently developed to improve patients' quality of life. In this review, we will summarize key studies of pathogenesis, related genes, risk factors and preventative methods on breast cancer over the past years. These findings represent a small step in the long fight against breast cancer.
                Bookmark

                Author and article information

                Journal
                Pharmgenomics Pers Med
                Pharmgenomics Pers Med
                pgpm
                Pharmacogenomics and Personalized Medicine
                Dove
                1178-7066
                11 January 2022
                2022
                : 15
                : 9-16
                Affiliations
                [1 ]School of Medicine, Southeast University , Nanjing, Jiangsu Province, 210096, People’s Republic of China
                [2 ]Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University , Nanjing, Jiangsu Province, 210006, People’s Republic of China
                [3 ]Department of Clinical Oncology, Queen Elizabeth Hospital , Hong Kong, People’s Republic of China
                [4 ]Department of General Surgery, Nanjing First Hospital, Nanjing Medical University , Nanjing, People’s Republic of China
                [5 ]Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University , Nanjing, People's Republic of China
                Author notes
                Correspondence: Shukui Wang School of Medicine, Southeast University , Nanjing, Jiangsu Province, 210096, People’s Republic of China Email sk_wang@njmu.edu.cn
                Bangshun He Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University , Nanjing, Jiangsu Province, 210006, People’s Republic of China Email bhe@njmu.edu.cn
                [*]

                These authors contributed equally to this work

                Author information
                http://orcid.org/0000-0003-4174-4586
                http://orcid.org/0000-0001-7812-6197
                Article
                328612
                10.2147/PGPM.S328612
                8761026
                35046699
                dbe07eb4-58c1-4fca-bed4-aeaff4263137
                © 2022 Wang et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 09 July 2021
                : 03 November 2021
                Page count
                Figures: 0, Tables: 12, References: 48, Pages: 8
                Funding
                Funded by: The National Nature Science Foundation of China;
                Funded by: Jiangsu Youth Medical Talents Training Project to BH;
                Funded by: the Innovation Team of Jiangsu Provincial Health-Strengthening Engineering by Science and Education;
                This study was supported by The National Nature Science Foundation of China (no. 82073288), Jiangsu Youth Medical Talents Training Project to BH (QNRC2016066), and the Innovation Team of Jiangsu Provincial Health-Strengthening Engineering by Science and Education (CXTDB2017008).
                Categories
                Original Research

                Pharmacology & Pharmaceutical medicine
                one-carbon metabolism,dna methylation,dnmt1,snp,breast cancer

                Comments

                Comment on this article